NOVO.B.DK

277.65

+1.83%↑

GMAB.DK

1,689.5

-0.03%↓

COLO.B.DK

402

+1.88%↑

ZEAL.DK

309.2

+3.27%↑

AMBUB.DK

65.2

+3.33%↑

NOVO.B.DK

277.65

+1.83%↑

GMAB.DK

1,689.5

-0.03%↓

COLO.B.DK

402

+1.88%↑

ZEAL.DK

309.2

+3.27%↑

AMBUB.DK

65.2

+3.33%↑

NOVO.B.DK

277.65

+1.83%↑

GMAB.DK

1,689.5

-0.03%↓

COLO.B.DK

402

+1.88%↑

ZEAL.DK

309.2

+3.27%↑

AMBUB.DK

65.2

+3.33%↑

NOVO.B.DK

277.65

+1.83%↑

GMAB.DK

1,689.5

-0.03%↓

COLO.B.DK

402

+1.88%↑

ZEAL.DK

309.2

+3.27%↑

AMBUB.DK

65.2

+3.33%↑

NOVO.B.DK

277.65

+1.83%↑

GMAB.DK

1,689.5

-0.03%↓

COLO.B.DK

402

+1.88%↑

ZEAL.DK

309.2

+3.27%↑

AMBUB.DK

65.2

+3.33%↑

Search

H Lundbeck A-S

Затворен

42.42 -0.98

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

42.24

Максимум

42.44

Ключови измерители

By Trading Economics

Приходи

-1.7B

-27M

Продажби

-465M

5.8B

P/E

Средно за сектора

13.17

49.8

EPS

0.94

Дивидентна доходност

2.71

Марж на печалбата

-0.464

Служители

5,039

EBITDA

130M

1.8B

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.71%

2.25%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.1B

42B

Предишно отваряне

43.4

Предишно затваряне

42.42

H Lundbeck A-S Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.05.2026 г., 23:41 ч. UTC

Печалби

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6.05.2026 г., 21:40 ч. UTC

Печалби

Nutrien Logs Higher Profit, Sales Growth in 1Q

6.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6.05.2026 г., 23:13 ч. UTC

Печалби

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6.05.2026 г., 23:13 ч. UTC

Печалби

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6.05.2026 г., 23:12 ч. UTC

Печалби

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6.05.2026 г., 23:11 ч. UTC

Печалби

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6.05.2026 г., 23:07 ч. UTC

Печалби

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6.05.2026 г., 23:06 ч. UTC

Печалби

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6.05.2026 г., 23:06 ч. UTC

Печалби

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6.05.2026 г., 23:05 ч. UTC

Печалби

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6.05.2026 г., 23:04 ч. UTC

Печалби

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6.05.2026 г., 22:50 ч. UTC

Печалби

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6.05.2026 г., 22:25 ч. UTC

Пазарно говорене

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6.05.2026 г., 22:11 ч. UTC

Печалби

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6.05.2026 г., 22:11 ч. UTC

Печалби

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6.05.2026 г., 22:05 ч. UTC

Пазарно говорене

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6.05.2026 г., 21:58 ч. UTC

Печалби

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6.05.2026 г., 21:47 ч. UTC

Пазарно говорене
Печалби

Costco Posts 13% Sales Growth in April -- Market Talk

6.05.2026 г., 21:46 ч. UTC

Печалби

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6.05.2026 г., 21:40 ч. UTC

Печалби

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6.05.2026 г., 21:35 ч. UTC

Пазарно говорене

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6.05.2026 г., 21:32 ч. UTC

Горещи акции

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6.05.2026 г., 21:29 ч. UTC

Печалби

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

H Lundbeck A-S Прогноза

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
help-icon Live chat